<DOC>
	<DOCNO>NCT01164176</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well everolimus work treat patient locally advance metastatic thyroid cancer .</brief_summary>
	<brief_title>Everolimus Treating Patients With Locally Advanced Metastatic Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate response rate patient locally advanced metastatic , unresectable refractory thyroid cancer treat everolimus . Secondary - To evaluate overall survival patient treat everolimus . - To evaluate progression-free survival patient . - To evaluate toxicity therapy patient . OUTLINE : This multicenter study . Patients receive oral everolimus daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Blood sample collect periodically correlative study . After completion study treatment , patient follow 12 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm thyroid cancer Progressive refractory disease within past 6 month Locally advance metastatic disease Measurable disease , define ≥ 1 measurable lesion define RECIST criterion Not amenable surgical resection externalbeam radiotherapy refractory radioiodine therapy No untreated brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine &lt; 1.5 mg/dL Total bilirubin ≤ 1.0 time upper limit normal ( ULN ) ALT AST ≤ 3.0 time ULN No known hypersensitivity study drug No serious uncontrolled systemic intercurrent illness ( e.g. , infection poorly control diabetes ) No history significant neurological mental disorder , include seizure dementia No malignancy within past 5 year except carcinoma situ cervix nonmelanomatous carcinoma skin No active uncontrolled cardiac disease No myocardial infarction within past 12 month Able take oral medication No active peptic ulcer disease Must patient compliance geographic proximity adequate followup PRIOR CONCURRENT THERAPY : At least 30 day since prior mTorinhibitor therapy ( e.g. , temsirolimus ) nonhormonal anticancer therapy At least 2 week since prior concurrent Pglycoprotein , CYP3A4 , CYP3A5 inhibitors inducer No prior surgical procedure affect absorption No concurrent systemic chemotherapy , investigational drug , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>stage III papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
</DOC>